Immunology / Virology & Vaccines

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

Listen now: Last episode of DDW Highlights for 2022

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The focus has been on immunotherapy and genetics this week, with exciting… Read More

#News

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

This week in drug discovery (12-16 December)

News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia.  The top stories: … Read More

#News

#Cancer research #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA #mRNA-based vaccines

mRNA cancer vaccine meets primary efficacy endpoint

Personalised mRNA vaccine mRNA-4157/V940 has demonstrated a clinically meaningful improvement in patients with late-stage melanoma.  The vaccine, in combination with Keytruda, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.  Adjuvant treatment with… Read More

#Cancer Research #News

Amaranth oil
#Biopharmaceuticals #Drug discovery #Immunology / Virology & Vaccines #Plant-based

Plant-based squalene alternative suitable for vaccine use

Evonik has launched a non-animal-derived squalene suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene on the market for use in adjuvants in parenteral dosage forms. It is an alternative to animal-derived squalene, which for pharmaceutical applications is typically sourced from shark liver oil. Read More

#News

Illustration of a virus
#Gene therapy #Genetic diseases #Immunology / Virology & Vaccines #Virus mutation

Ancient viruses may hold key to gene therapy treatments

Scientists have unlocked key insights into virus evolution, revealing new information that could help develop treatments for a wide variety of genetic diseases.  The research focuses on a group of small, ubiquitous viruses called ‘parvoviruses’ (from the Latin word ‘parvus’ meaning ‘small’, ‘puny’ or ‘unimportant’). Read More

#Editor's Choice #News

Dr Noushin Jaberolansar and Dr Andrew Young at lab bench
#Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response

Clamp2 provides vaccine hope for future pandemics

The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial.  The Coalition for Epidemic Preparedness Innovation (CEPI) has committed up to AU$8.5 ($5.7) million to support further development of the re-engineered technology for use in the global response to… Read More

#News

Monkeypox virus
#Antivirals #DNA mutations #Immunology / Virology & Vaccines #Monkeypox #Monkeypox vaccine #Virus mutation

Researchers reveal how monkeypox evolves to evade drugs 

A team of scientists has identified the specific mutations in the monkeypox virus that contribute to its continued infectiousness. Monkeypox has infected more than 77,000 people in more than 100 countries worldwide. Mutations have enabled the virus to grow stronger and smarter, evading antiviral drugs and… Read More

#News #Trending News

#Cancer research #Cancer vaccine #Immuno-oncology #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines

Merck and Moderna to jointly develop personalised cancer vaccine 

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna.   mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk… Read More

#Cancer Research #News

#Covid-19 #Geographic atrophy #Immunology / Virology & Vaccines #Malaria #Neuroscience #Psychedelics

Catch up on the latest DDW Highlights episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a week that saw magic mushrooms making the… Read More

#News

#Business #GSK #Immunology / Virology & Vaccines #Pharmaceuticals

GSK reports strong Q3 results  

GSK has announced strong quarterly results, reporting sales of £7.8 billion and growth in various sectors of the business.   Overall, the company’s adjusted operating profit for the third quarter came in at £2.6 billion, a 17% increase compared to the same period last year and reflecting a 4% year-on-growth at… Read More

#Business & Investment

Covid-19 vaccination
#Covid-19 #Covid-19 vaccine #Immunocompromised #Immunology / Virology & Vaccines

Covid-19 vaccine less effective in the immunocompromised 

A new study in the US has revealed that the Covid-19 vaccine is less effective in people with weakened immune systems.  The research from the Centers for Disease Control and Prevention’s VISION Network analysed real-world data on mRNA vaccine effectiveness during Omicron BA.4 and BA.5 predominance… Read More

#Covid-19 #News #Trending News

Bananas
#Antivirals #Genetic engineering #Immunology / Virology & Vaccines #Proteins

Engineered banana lectin could become broad spectrum antiviral 

An international team of scientists have engineered protein banana lectin, or BanLec, to create a new version that can fight off a range of viruses without unwanted side effects.  The genetically engineered version has been called H84T and worked against the viruses that cause AIDS, hepatitis… Read More

#News

Shingles
#Clinical trial #GSK #Immunology / Virology & Vaccines #Recombinant Zoster Vaccine #Shingles

Shingles vaccine provides protection for a decade

New data have shown that GSK’s Shingrix provides at least 10 years of protection against shingles in adults aged 50 years and over. In the primary endpoint, the interim data demonstrated overall efficacy of greater than 80% over the follow-up period of approximately six to 10 years after initial vaccination. Read More

#News

RNA vaccine
#Cancer research #Cancer vaccine #Immuno-oncology #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA

Merck and Moderna to develop personalised cancer vaccine

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The companies will report data from the ongoing Phase II trial of mRNA-4157/V940 in combination with KEYTRUDA in high-risk melanoma later this year. “We have been collaborating with Merck… Read More

#Cancer Research #News #Trending News

#Biotechnology #Data #Immunology / Virology & Vaccines #In Silico Biology

Sekkei Bio implements system to centralise research data 

Sekkei Bio, an India-based company dedicated to building technologies for drug and vaccine design with global impact, has implemented CDD Vault as the main platform to house its research data.   Sekkei Bio has made progress toward finding therapies for diabetes and pain, and has a management team… Read More

#News

#Clinical development #Immunology / Virology & Vaccines #Infectious diseases #mRNA #Public health

mRNA technology may hold the future for a cytomegalovirus vaccine 

Listen to this article on the DDW podcast: Allison August, M.D., Vice President, Clinical Development, Infectious Diseases at Moderna examines the data on cytomegalovirus (CMV), why attempts at vaccines for CMV have so far proved elusive and the emerging options to address this unmet need.  Although cytomegalovirus (CMV) is almost… Read More

#Exclusive Content #Trends & Analysis